Advertisement
Product › Details
Intuvax®
Next higher product group | cell therapy product_oo | |
Status | 2016-04-25 development p2 existent | |
Organisation | Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST) | |
Today | Mendus AB (publ) (Nasdaq Stockholm: IMMU.ST) | |
Group | Mendus (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for Intuvax®
- [1] Immunicum AB. (8/18/17). "Press Release: Interim Report Q2 – Corporate Update and Outlook"....
- [2] Immunicum AB. (8/17/17). "Press Release: Immunicum Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel"....
- [3] Immunicum AB. (5/19/17). "Press Release: Quarterly Report January-March 2017"....
- [4] Immunicum AB. (3/2/17). "Press Release: Immunicum AB Appoints Sijme Zeilemaker as Senior Director Business Development". Gothenburg....
- [5] Immunicum AB. (2/17/17). "Press Release: Year-end Report 2016 (July 2016 – December 2016)". Gothenburg....
- [6] Immunicum AB. (2/14/17). "Press Release: Immunicum AB Announces Approval in France for Its Clinical Trial Application for Intuvax in Metastatic Renal Cell Carcinoma". Gothenburg....
- [7] Immunicum AB. (2/13/17). "Press Release: Immunicum AB Appoints Karin Hoogendoorn as Head of CMC". Gothenburg....
- [8] Immunicum AB. (2/3/17). "Press Release: Immunicum AB CEO to present at BIO CEO & Investor Conference". Gothenburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top